Samer Ezziddin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9149201/publications.pdf

Version: 2024-02-01

128	5,218	94415	95259
papers	citations	37 h-index	68 g-index

134	134	134	4793
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology, 2011, 54, 868-878.	7.3	550
2	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2536-2544.	6.4	265
3	Research Reporting Standards for Radioembolization of Hepatic Malignancies. Journal of Vascular and Interventional Radiology, 2011, 22, 265-278.	0.5	185
4	Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 59-67.	6.4	166
5	Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 925-933.	6.4	165
6	Radioembolization of Liver Tumors With Yttrium-90 Microspheres. Seminars in Nuclear Medicine, 2010, 40, 105-121.	4.6	160
7	Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2014, 55, 183-190.	5.0	158
8	Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 Hydroxyethylidenediphosphonate. Journal of Clinical Oncology, 2003, 21, 2869-2875.	1.6	157
9	Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2013, 54, 1857-1861.	5.0	128
10	225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 721-728.	6.4	126
11	The Significance of ^{99m}Tc-MAA SPECT/CT Liver Perfusion Imaging in Treatment Planning for ⁹⁰Y-Microsphere Selective Internal Radiation Treatment. Journal of Nuclear Medicine, 2010, 51, 1206-1212.	5.0	114
12	Osteoporosis in haemophilia ? an underestimated comorbidity?. Haemophilia, 2007, 13, 79-84.	2.1	106
13	Specific efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced neuroendocrine tumours of the small intestine. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1238-1246.	6.4	91
14	Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 205-210.	6.4	87
15	Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 459-466.	6.4	84
16	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 753-761.	3.7	82
17	Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1118-1124.	6.4	80
18	131I-Metaiodobenzylguanidine Therapy of Neuroblastoma and Other Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2010, 40, 153-163.	4.6	80

#	Article	IF	Citations
19	Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. European Journal of Cancer, 2016, 58, 41-51.	2.8	80
20	Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 505-510.	6.4	76
21	Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System. Journal of Nuclear Medicine, 2014, 55, 1260-1266.	5.0	76
22	Palliation and Survival After Repeated ¹⁸⁸Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis. Journal of Nuclear Medicine, 2011, 52, 1721-1726.	5.0	63
23	Does the Pretherapeutic Tumor SUV in 68Ga DOTATOC PET Predict the Absorbed Dose of 177Lu Octreotate?. Clinical Nuclear Medicine, 2012, 37, e141-e147.	1.3	62
24	⁹⁰Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2012, 53, 1663-1669.	5.0	62
25	Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-Octreotate. Journal of Nuclear Medicine, 2011, 52, 1197-1203.	5.0	59
26	Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Research, 2008, 18, 346-352.	1.2	58
27	Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. Journal of Nuclear Medicine, 2006, 47, 223-33.	5.0	57
28	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. Clinical Research in Cardiology, 2016, 105, 364-371.	3.3	54
29	The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 309-315.	6.4	52
30	Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 370-376.	6.4	52
31	Imaging of prostate cancer metastases with 18 F-fluoroacetate using PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 797-797.	6.4	51
32	False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer, 2007, 58, 418-421.	2.0	51
33	EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 846-859.	6.4	51
34	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). CardioVascular and Interventional Radiology, 2021, 44, 21-35.	2.0	49
35	Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 80-90.	6.4	44
36	Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. European Radiology, 2014, 24, 2482-2490.	4.5	43

#	Article	IF	Citations
37	Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2040-2041.	6.4	42
38	Radium-223 in Prostate Cancer. New England Journal of Medicine, 2013, 369, 1659-1660.	27.0	40
39	New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 687-694.	6.4	38
40	Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy. Theranostics, 2021, 11, 4050-4060.	10.0	38
41	177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1075-1085.	6.4	37
42	Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-Related Cancer, 2016, 23, C1-C7.	3.1	36
43	Advances in Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine, 2016, 46, 40-46.	4.6	34
44	The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. Journal of Cancer Research and Clinical Oncology, 2004, 130, 649-656.	2.5	31
45	Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with 99mTc-MAA accumulation in the anterior abdominal wall?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1477-1484.	6.4	31
46	Can peptide receptor radionuclide therapy be safely applied in florid bone metastases?. Nuklearmedizin - NuclearMedicine, 2014, 53, 54-59.	0.7	31
47	Impact of Dual-Time-Point F-18 FDG PET/CT in the Assessment of Pleural Effusion in Patients With Non-Small-Cell Lung Cancer. Clinical Nuclear Medicine, 2011, 36, 423-428.	1.3	30
48	The Value of F-18 FDG PET in Patients With Primary Sclerosing Cholangitis and Cholangiocarcinoma Using Visual and Semiquantitative Analysis. Clinical Nuclear Medicine, 2011, 36, 879-883.	1.3	30
49	Neoadjuvant Downsizing by Internal Radiation. Clinical Nuclear Medicine, 2012, 37, 102-104.	1.3	30
50	Significance of Oral Administration of Sodium Perchlorate in Planning Liver-Directed Radioembolization. Journal of Nuclear Medicine, 2011, 52, 1063-1067.	5.0	29
51	Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Nuklearmedizin - NuclearMedicine, 2014, 53, 39-45.	0.7	28
52	Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report. Radiation Oncology, 2011, 6, 94.	2.7	27
53	Robotic salvage lymph node dissection for nodal-only recurrences after radical prostatectomy: Perioperative and early oncological outcomes. Surgical Oncology, 2018, 27, 138-145.	1.6	27
54	Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 103-112.	6.4	27

#	Article	IF	Citations
55	Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. Cancers, 2021, 13, 3095.	3.7	27
56	Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Research, 2013, 3, 82.	2.5	26
57	Diffusion-weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. European Radiology, 2014, 24, 267-276.	4.5	26
58	⁶⁸Ga-DOTATOC PET/CT in Patients with Iodine- and ¹⁸F-FDGâ€“Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin. Journal of Nuclear Medicine, 2016, 57, 1512-1517.	5.0	26
59	Long-Term Outcome and Toxicity After Dose-Intensified Treatment with ¹³¹I-MIBG for Advanced Metastatic Carcinoid Tumors. Journal of Nuclear Medicine, 2013, 54, 2032-2038.	5.0	25
60	Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy. European Radiology, 2017, 27, 966-975.	4.5	25
61	Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceutics, 2021, 13, 722.	4.5	25
62	Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry. Recent Results in Cancer Research, 2013, 194, 457-465.	1.8	24
63	Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1584-1594.	6.4	24
64	Efficacy of peptide receptor radionuclide therapy with Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 74-83.	1.0	23
65	Feasibility of temporary protective embolization of normal liver tissue using degradable starch microspheres during radioembolization of liver tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 231-237.	6.4	22
66	Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. European Radiology, 2015, 25, 2693-2700.	4.5	22
67	89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2064-2076.	6.4	22
68	Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy?. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 608-612.	6.4	20
69	99mTc-MAA/90Y-Bremsstrahlung SPECT/CT after simultaneous Tc-MAA/90Y-microsphere injection for immediate treatment monitoring and further therapy planning for radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1281-1288.	6.4	20
70	Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1531-1541.	2.5	20
71	¹⁷⁷Lu-Prostate-Specific Membrane Antigen Ligand After ²²³Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience. Journal of Nuclear Medicine, 2022, 63, 410-414.	5.0	19
72	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 71-78.	3.9	19

#	Article	IF	Citations
73	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1721-1730.	6.4	18
74	Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 437-45.	1.0	18
75	Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1971-1975.	6.4	17
76	Pretreatment Dosimetry in HCC Radioembolization with 90Y Glass Microspheres Cannot Be Invalidated with a Bare Visual Evaluation of 99mTc-MAA Uptake of Colorectal Metastases Treated with Resin Microspheres. Journal of Nuclear Medicine, 2014, 55, 1215-1216.	5.0	16
77	Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [¹⁷⁷Lu]Lu-PSMA-617. Journal of Medicinal Chemistry, 2021, 64, 4960-4971.	6.4	16
78	Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. EJNMMI Research, 2020, 10, 52.	2.5	16
79	111In-Pentetreotide scintigraphy in medulloblastoma: A comparison with magnetic resonance imaging. Acta OncolÃ³gica, 2007, 46, 111-117.	1.8	15
80	Early prediction of tumour response to PRRT. Nuklearmedizin - NuclearMedicine, 2013, 52, 170-177.	0.7	15
81	Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT. Cancers, 2021, 13, 4134.	3.7	15
82	Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 190-195.	6.4	14
83	Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. Biomolecules, 2021, 11, 1099.	4.0	14
84	The Importance of Tc-MAA SPECT/CT for Therapy Planning of Radioembolization in a Patient Treated With Bevacizumab. Clinical Nuclear Medicine, 2012, 37, 1129-1130.	1.3	13
85	The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer. PLoS ONE, 2016, 11, e0162816.	2.5	13
86	Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me. Organic and Biomolecular Chemistry, 2018, 16, 7503-7512.	2.8	12
87	Radiosynoviorthesis in hemophilic arthropathy: pathologic blood pool imaging on pre-therapeutic bone scintigraphy is not a predictor of treatment success. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 461-467.	6.4	11
88	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. Cancers, 2022, 14, 1696.	3.7	10
89	Reduced MIBG accumulation of the parotid and submandibular glands in idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2017, 34, 26-30.	2.2	9
90	Dual-Time F-18 FDG-PET/CT Imaging for Diagnosis of Occult Non-Hodgkin Lymphoma in a Patient With Esophageal Cancer. Clinical Nuclear Medicine, 2009, 34, 168-170.	1.3	8

#	Article	IF	Citations
91	Splenic Infarction Mimicking a Necrotizing Metastasis of Malignant Melanoma on F-18 FDG PET/CT. Clinical Nuclear Medicine, 2008, 33, 571-572.	1.3	7
92	Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. Nuklearmedizin - NuclearMedicine, 2014, 53, 46-53.	0.7	7
93	Residual activity after radioembolization of liver tumours with 90Y resin microspheres. Nuklearmedizin - NuclearMedicine, 2014, 53, 95-98.	0.7	7
94	Determination of split renal function by PSMA imaging: comparison of Ga-PSMA-11 PET with Tc-MAG3 scintigraphy. American Journal of Nuclear Medicine and Molecular Imaging, 2020, 10, 249-256.	1.0	7
95	Survival After Accidental Extrahepatic Distribution of Y90 Microspheres to the Mesentery During a Radioembolization Procedure. CardioVascular and Interventional Radiology, 2012, 35, 954-957.	2.0	6
96	Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management. Journal of Urology, 2021, 206, 88-96.	0.4	6
97	Osseous metastases of gastro- entero - pancreatic neuroendocrine tumours. Nuklearmedizin - NuclearMedicine, 2012, 51, 95-100.	0.7	5
98	Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG. Radiation Oncology, 2012, 7, 8.	2.7	5
99	Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative 124I-NaI-PET/CT in patients with papillary thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1988-1994.	6.4	5
100	Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems. Applied Radiation and Isotopes, 2021, 170, 109599.	1.5	5
101	Subclinical hyperthyroidism seems not to have a significant impact on systemic anticoagulation in patients with coumarin therapy. Thrombosis and Haemostasis, 2008, 100, 803-809.	3.4	5
102	Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failureâ€"Preliminary Evidence of Pilot Experience. Cancers, 2022, 14, 2691.	3.7	5
103	Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine. British Journal of Radiology, 2006, 79, e84-e87.	2.2	4
104	Treatment options for haemophilic arthropathy of the elbow after failed conservative therapy. Hamostaseologie, 2014, 34, S17-S22.	1.9	4
105	MIBG scintigraphy of the major salivary glands in progressive supranuclear palsy and corticobasal degeneration. Parkinsonism and Related Disorders, 2019, 66, 247-248.	2.2	4
106	Large Paraesophageal Schwannoma With Intense Prostate-Specific Membrane Antigen Expression on 68Ga-PSMA-PET/CT Mimicking Lymph Node Metastasis in a Patient With Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, 153-154.	1.3	4
107	Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates. Molecular Imaging and Biology, 2021, 23, 95-108.	2.6	4
108	May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on (188)Re-HEDP treatment in progressive bone metastases after (177)Lu-octreotate. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 4, 80-8.	1.0	4

#	Article	IF	Citations
109	MIBG scintigraphy of the major salivary glands in multiple system atrophy. Parkinsonism and Related Disorders, 2018, 53, 112-114.	2.2	3
110	Striatal dopamine transporters and cognitive function in Parkinsonâ€™s disease. Acta Neurologica Scandinavica, 2020, 142, 385-391.	2.1	3
111	Introduction of a metabolic joint asymmetry score derived from conventional bone scintigraphy. Nuklearmedizin - NuclearMedicine, 2015, 54, 183-189.	0.7	3
112	Impact of Thyroid Metabolism on the Course of INR Levels in a Patient with Systemic Anticoagulation Suffering from Amiodarone-Induced Thyrotoxicosis. Experimental and Clinical Endocrinology and Diabetes, 2007, 115, 606-609.	1.2	2
113	Single- vs. dual-head SPECT for detection of myocardial ischemia and viability in a large study population. Clinical Imaging, 2007, 31, 228-233.	1.5	2
114	Somatostatin receptor scintigraphy in the follow-up of myasthenia gravis. Neurological Sciences, 2007, 28, 175-180.	1.9	2
115	Disease characteristics and outcome of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received a beta emitter (177Lu-PSMA) after an alpha emitter (radium-223).. Journal of Clinical Oncology, 2020, 38, e17592-e17592.	1.6	2
116	Therapy of hepatocellular carcinoma with 131I-lipiodol: patient dosimetry. Nuklearmedizin - NuclearMedicine, 2007, 46, 192-197.	0.7	1
117	Hypertrophy of the contralateral hepatic lobe after selective internal radiation therapy. European Journal of Cancer, Supplement, 2012, 10, 44-45.	2.2	1
118	Comment on Campana et al.: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 174-175.	6.4	1
119	Liver and lymph node metastases of prostate cancer visualized on post-therapy imaging after treatment with 188Re-HEDP. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2014, 33, 58-59.	0.0	1
120	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Pharmaceuticals, 2021, 14, 1022.	3.8	1
121	Incremental diagnostic value of SPET/CT in precise localization of extraskeletal uptake of bone-seeking agents in multiple myeloma. Hellenic Journal of Nuclear Medicine, 2010, 13, 285-6.	0.3	1
122	Radioembolization With 90Y Resin Microspheres for HCC Patients With Extensive Tumor Thrombosis Into the Extrahepatic Vessels. Clinical Nuclear Medicine, 2014, 39, 305-307.	1.3	0
123	Recovery of Renal Function Under PSMA Mediated Radioligand Therapy of Advanced Metastasized Castration Resistant Prostate Cancer. Clinical Nuclear Medicine, 2019, 44, 730-731.	1.3	0
124	Treatment Option not Mentioned. Deutsches Ärzteblatt International, 2013, 110, 612.	0.9	0
125	Diagnosis of extraadrenal phaeochromocytoma after nephrectomy. Central European Journal of Urology, 2014, 67, 162-6.	0.3	0
126	Radioembolization as a Treatment Option. Deutsches Ärzteblatt International, 2015, 112, 372-3.	0.9	0

#	Article	IF	Citations
127	Systemic Mastocytosis Treatment with Midostaurin: [18F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome. Diagnostics, 2022, 12, 680.	2.6	0
128	PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [68Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression. Diagnostics, 2022, 12, 1211.	2.6	0